Epigenetically downregulated Semaphorin 3E contributes to gastric cancer

Hui Chen; Guo-Hua Xie; Wei-Wei Wang; Xiang-Liang Yuan; Wen-Ming Xing; Hong-Jing Liu; Jin Chen; Min Dou; Li-Song Shen

doi:10.18632/oncotarget.3936

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Epigenetically downregulated Semaphorin 3E contributes to gastric cancer

Hui Chen, Guo-Hua Xie, Wei-Wei Wang, Xiang-Liang Yuan, Wen-Ming Xing, Hong-Jing Liu, Jin Chen, Min Dou and Li-Song Shen _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:20449-20465. https://doi.org/10.18632/oncotarget.3936

Metrics: PDF 2361 views | HTML 2347 views | ?

Abstract

Hui Chen1, Guo-Hua Xie1, Wei-Wei Wang1, Xiang-Liang Yuan1, Wen-Ming Xing2, Hong-Jing Liu1, Jin Chen1, Min Dou1, Li-Song Shen1

1Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

2Department of Academy, Shanghai Association for Science & Technology, Shanghai 200020, China

Correspondence to:

Li-Song Shen, e-mail: [email protected]

Keywords: Sema3E, gastric cancer, epigenetics, proliferation, migration

Received: January 23, 2015 Accepted: April 29, 2015 Published: May 12, 2015

ABSTRACT

Axon guidance protein Semaphorin 3E (Sema3E) promotes tumor metastasis and suppresses tumor cell death. Here, we demonstrated that Sema3E was decreased in gastric cancer. Its levels were inversely associated with tumor progression. Levels of Sema3E were associated with low p300 and high class I histone deacetylase (class I HDAC). Ectopic expression of Sema3E inhibited proliferation and colony formation of gastric cancer cell lines in vitro and xenografts in vivo. Sema3E overexpression inhibited migration and invasion of gastric cancer cells, which was associated with induction of E-cadherin and reduction of Akt and ERK1/2 phosphorylation. We suggest that silencing of Sema3E contributes to the pathogenesis of gastric cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3936

Publication Alerts

Research Papers:

Epigenetically downregulated Semaphorin 3E contributes to gastric cancer

Abstract